← Back to Search
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging (CAPTIVA-MRI Trial)
Birmingham, AL
N/A
Recruiting
Led By Sepideh Amin-Hanjani, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPTIVA-MRI study leverages the CAPTIVA trial design and implementation to capture information that will inform and facilitate the next generation of ICAS trials and the management of patients with ICAS.
Eligible Conditions
- Stroke
- Intracranial Atherosclerotic Stenosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Establish ICAS hemodynamic and plaque MRI biomarkers as reliable predictors of recurrent ischemic stroke in the vascular territory of the index stroke.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CAPTIVA-MRI GroupExperimental Treatment1 Intervention
CAPTIVA patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.
Find a Location
Closest Location:University of Alabama Hospital· Birmingham, AL· 494 miles
Who is running the clinical trial?
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,399 Previous Clinical Trials
655,817 Total Patients Enrolled
179 Trials studying Stroke
79,993 Patients Enrolled for Stroke
Yale UniversityLead Sponsor
1,953 Previous Clinical Trials
3,043,256 Total Patients Enrolled
18 Trials studying Stroke
16,284 Patients Enrolled for Stroke
Sepideh Amin-Hanjani, MDPrincipal InvestigatorUniversity Hospitals
2 Previous Clinical Trials
241 Total Patients Enrolled
2 Trials studying Stroke
241 Patients Enrolled for Stroke
Rano Chatterjee, MDPrincipal InvestigatorWashington University School of Medicine
David Liebeskind, MDPrincipal InvestigatorUniversity of California, Los Angeles